Reduction In Cardiovascular Death Shown For The First Time With New Oral Antiplatelet Agent Ticagrelor

The presentation of the PLATO (A Study of Platelet Inhibition and Patient Outcomes), showed that ticagrelor (Brilinta®) reduced the rate of cardiovascular (CV) events (CV death, myocardial infarction or stroke) from 11.7% to 9.8% compared clopidogrel (Plavix®) XX% (p About Ticagrelor Ticagrelor is the first reversibly binding oral adenosine diphosphate (ADP) receptor antagonist.